These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 34797780)

  • 1. The Impact of KRAS Mutation in Patients With Sporadic Nonampullary Duodenal Epithelial Tumors.
    Kinugasa H; Kanzaki H; Tanaka T; Yamamoto S; Yamasaki Y; Nouso K; Ichimura K; Nakagawa M; Mitsuhashi T; Okada H
    Clin Transl Gastroenterol; 2021 Nov; 12(11):e00424. PubMed ID: 34797780
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular markers identify subtypes of stage III colon cancer associated with patient outcomes.
    Sinicrope FA; Shi Q; Smyrk TC; Thibodeau SN; Dienstmann R; Guinney J; Bot BM; Tejpar S; Delorenzi M; Goldberg RM; Mahoney M; Sargent DJ; Alberts SR
    Gastroenterology; 2015 Jan; 148(1):88-99. PubMed ID: 25305506
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular alterations and PD-L1 expression in non-ampullary duodenal adenocarcinoma: Associations among clinicopathological, immunophenotypic and molecular features.
    Watari J; Mitani S; Ito C; Tozawa K; Tomita T; Oshima T; Fukui H; Kadowaki S; Natsume S; Senda Y; Tajika M; Hara K; Yatabe Y; Shimizu Y; Muro K; Morimoto T; Hirota S; Das KM; Miwa H
    Sci Rep; 2019 Jul; 9(1):10526. PubMed ID: 31324814
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Comparative analysis of real-time quantitative PCR-Sanger sequencing method and TaqMan probe method for detection of KRAS/BRAF mutation in colorectal carcinomas].
    Zhang X; Wang Y; Gao N; Wang J
    Zhonghua Bing Li Xue Za Zhi; 2014 Feb; 43(2):77-82. PubMed ID: 24742565
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship between gene mutations and clinicopathological features in nonampullary duodenal epithelial tumors.
    Fukusada S; Shimura T; Iwasaki H; Okuda Y; Katano T; Ozeki T; Kitagawa M; Nishie H; Tanaka M; Ozeki K; Kubota E; Tanida S; Kataoka H
    Dig Liver Dis; 2022 Jul; 54(7):905-910. PubMed ID: 34961702
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinicopathologic and prognostic associations of KRAS and BRAF mutations in small intestinal adenocarcinoma.
    Jun SY; Kim M; Jin Gu M; Kyung Bae Y; Chang HK; Sun Jung E; Jang KT; Kim J; Yu E; Woon Eom D; Hong SM
    Mod Pathol; 2016 Apr; 29(4):402-15. PubMed ID: 26892442
    [TBL] [Abstract][Full Text] [Related]  

  • 7. KRAS G>A mutation favors poor tumor differentiation but may not be associated with prognosis in patients with curatively resected duodenal adenocarcinoma.
    Fu T; Guzzetta AA; Jeschke J; Vatapalli R; Dave P; Hooker CM; Morgan R; Iacobuzio-Donahue CA; Liu B; Ahuja N
    Int J Cancer; 2013 Jun; 132(11):2502-9. PubMed ID: 23065691
    [TBL] [Abstract][Full Text] [Related]  

  • 8. KRAS and BRAF gene mutations and DNA mismatch repair status in Chinese colorectal carcinoma patients.
    Ye JX; Liu Y; Qin Y; Zhong HH; Yi WN; Shi XY
    World J Gastroenterol; 2015 Feb; 21(5):1595-605. PubMed ID: 25663779
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutation status and prognostic value of KRAS and NRAS mutations in Moroccan colon cancer patients: A first report.
    El Agy F; El Bardai S; El Otmani I; Benbrahim Z; Karim MH; Mazaz K; Benjelloun EB; Ousadden A; El Abkari M; Ibrahimi SA; Chbani L
    PLoS One; 2021; 16(3):e0248522. PubMed ID: 33784337
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Frequent GNAS and KRAS mutations in pyloric gland adenoma of the stomach and duodenum.
    Matsubara A; Sekine S; Kushima R; Ogawa R; Taniguchi H; Tsuda H; Kanai Y
    J Pathol; 2013 Mar; 229(4):579-87. PubMed ID: 23208952
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial.
    Roth AD; Tejpar S; Delorenzi M; Yan P; Fiocca R; Klingbiel D; Dietrich D; Biesmans B; Bodoky G; Barone C; Aranda E; Nordlinger B; Cisar L; Labianca R; Cunningham D; Van Cutsem E; Bosman F
    J Clin Oncol; 2010 Jan; 28(3):466-74. PubMed ID: 20008640
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BRAF-mutated, microsatellite-stable adenocarcinoma of the proximal colon: an aggressive adenocarcinoma with poor survival, mucinous differentiation, and adverse morphologic features.
    Pai RK; Jayachandran P; Koong AC; Chang DT; Kwok S; Ma L; Arber DA; Balise RR; Tubbs RR; Shadrach B; Pai RK
    Am J Surg Pathol; 2012 May; 36(5):744-52. PubMed ID: 22314188
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low incidence of KRAS, BRAF, and PIK3CA mutations in adenocarcinomas of the ampulla of Vater and their prognostic value.
    Kwon MJ; Kim JW; Jung JP; Cho JW; Nam ES; Cho SJ; Kim JS; Park HR; Min SK; Seo J; Min KW; Kim DH; Jeon JY
    Hum Pathol; 2016 Apr; 50():90-100. PubMed ID: 26997442
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of DNA Mismatch Repair and Mutations in BRAF and KRAS With Survival After Recurrence in Stage III Colon Cancers : A Secondary Analysis of 2 Randomized Clinical Trials.
    Sinicrope FA; Shi Q; Allegra CJ; Smyrk TC; Thibodeau SN; Goldberg RM; Meyers JP; Pogue-Geile KL; Yothers G; Sargent DJ; Alberts SR
    JAMA Oncol; 2017 Apr; 3(4):472-480. PubMed ID: 28006055
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic Value of KRAS Mutation Subtypes and PD-L1 Expression in Patients With Lung Adenocarcinoma.
    Tao L; Miao R; Mekhail T; Sun J; Meng L; Fang C; Guan J; Jain A; Du Y; Allen A; Rzeszutko BL; Socinski MA; Chang CC
    Clin Lung Cancer; 2021 Jul; 22(4):e506-e511. PubMed ID: 32807653
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunohistochemical and molecular features of sporadic and FAP-associated duodenal adenomas of the ampullary and nonampullary mucosa.
    Wagner PL; Chen YT; Yantiss RK
    Am J Surg Pathol; 2008 Sep; 32(9):1388-95. PubMed ID: 18670349
    [TBL] [Abstract][Full Text] [Related]  

  • 17. KRAS codon 12 and 13 mutations in relation to disease-free survival in BRAF-wild-type stage III colon cancers from an adjuvant chemotherapy trial (N0147 alliance).
    Yoon HH; Tougeron D; Shi Q; Alberts SR; Mahoney MR; Nelson GD; Nair SG; Thibodeau SN; Goldberg RM; Sargent DJ; Sinicrope FA;
    Clin Cancer Res; 2014 Jun; 20(11):3033-43. PubMed ID: 24687927
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activating GNAS and KRAS mutations in gastric foveolar metaplasia, gastric heterotopia, and adenocarcinoma of the duodenum.
    Matsubara A; Ogawa R; Suzuki H; Oda I; Taniguchi H; Kanai Y; Kushima R; Sekine S
    Br J Cancer; 2015 Apr; 112(8):1398-404. PubMed ID: 25867268
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fusobacterium nucleatum in colorectal carcinoma tissue and patient prognosis.
    Mima K; Nishihara R; Qian ZR; Cao Y; Sukawa Y; Nowak JA; Yang J; Dou R; Masugi Y; Song M; Kostic AD; Giannakis M; Bullman S; Milner DA; Baba H; Giovannucci EL; Garraway LA; Freeman GJ; Dranoff G; Garrett WS; Huttenhower C; Meyerson M; Meyerhardt JA; Chan AT; Fuchs CS; Ogino S
    Gut; 2016 Dec; 65(12):1973-1980. PubMed ID: 26311717
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Globo H expression is associated with driver mutations and PD-L1 expressions in stage I non-small cell lung cancer.
    Yang CY; Lin MW; Chang YL; Wu CT
    Cancer Biomark; 2017 Dec; 21(1):211-220. PubMed ID: 29036791
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.